Literature DB >> 2783889

Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer.

R Bilik1, C Mor, B Hazaz, C Moroz.   

Abstract

Characterization of T-lymphocyte subpopulations adjacent to and infiltrating the primary tumor of breast cancer was carried out using a direct immunofluorescence procedure with the antibodies anti-(Leu-2a) for suppressor/cytotoxic (CD8+) and anti-(Leu-3a) for helper/inducer (CD4+) T-lymphocytes. Fifty-six primary malignant tumors with lymphoid infiltration were studied. The majority (58.9%) were infiltrating duct carcinoma. There were metastases to axillary lymph nodes in 6.67% of the patients. Massive lymphoid infiltration (greater than 40 lymphocytes per x 400 microscopic field) was found in 19.6% of the tumors and moderate infiltration (20-40 lymphocytes per field) in 51.8%. In all the tumors studied there was a reversed CD4+/CD8+ ratio as compared to that found in normal peripheral blood. In 66.1% the CD4+/CD8+ ratio (helper/suppressor) was less than 1.0. The reversed ratio was due to a significant decrease in the number of helper cells (P less than 0.0005). The most significant drop was in the stroma area (P less than 0.0001) as well as in the tumor tissue (P = 0.001). Of particular interest was the significant positive correlation between the age of the patients and an increased number of CD4+lymphocytes in the stroma (P = 0.02). Significant negative correlations were found between a reduced number of CD4+ lymphocytes or CD4+/CD8+ ratio and several histological parameters: tumor diameter, pleomorphism, nucleus/cytoplasm ratio. There was also a significant positive correlation between the total number of CD8+ lymphocytes infiltrating the tumor tissue and the number of axillary lymph nodes with metastatic disease (P = 0.03). It is suggested that the reversed ratio of CD4+/CD8+ lymphocytes may significantly affect the host/tumor immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783889     DOI: 10.1007/BF00199115

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

1.  Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours.

Authors:  B M Vose; M Moore
Journal:  Int J Cancer       Date:  1979-11-15       Impact factor: 7.396

2.  Some international differences in histology and survival in breast cancer.

Authors:  A S Morrison; M M Black; C R Lowe; B MacMahon; S Yuasa
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

3.  Reduced lymphocyte transformation in breast cancer.

Authors:  M G Whittaker; K Rees; C G Clark
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

4.  Impaired immunologic reactivity and recurrence following cancer surgery.

Authors:  F R Eilber; D L Morton
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

5.  Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

Authors:  S Rosenberg
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

6.  Predictors of recurrence in stage I (T1N0M0) breast carcinoma.

Authors:  P P Rosen; P E Saigo; D W Braun; E Weathers; A DePalo
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

7.  Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years.

Authors:  H J Bloom; W W Richardson; J R Field
Journal:  Br Med J       Date:  1970-07-25

8.  Possible host resistance in carcinoma of the breast: a histological study.

Authors:  I M Hamlin
Journal:  Br J Cancer       Date:  1968-09       Impact factor: 7.640

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man.

Authors:  E G Engleman; C J Benike; E Glickman; R L Evans
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more
  13 in total

1.  Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.

Authors:  H R Rosen; C Moroz; A Reiner; M Reinerova; M Stierer; J Svec; M Schemper; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

3.  Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.

Authors:  E Garaci; A Mastino; F Pica; C Favalli
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

Authors:  Marta Santisteban; Jennifer M Reiman; Michael K Asiedu; Marshall D Behrens; Aziza Nassar; Kimberly R Kalli; Paul Haluska; James N Ingle; Lynn C Hartmann; Masoud H Manjili; Derek C Radisky; Soldano Ferrone; Keith L Knutson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

5.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

6.  Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.

Authors:  H Inoue; M Adachi; N Karimine; S Arinaga; H Ueo; D Korenaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.

Authors:  R Dadmarz; M K Sgagias; S A Rosenberg; D J Schwartzentruber
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Principal lymphocyte subpopulation in local host response to human oesophageal cancer.

Authors:  H Tahara; H Siozaki; K Kobayashi; H Yano; S Tamura; M Miyata; K Wakasa; M Sakurai; T Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

9.  Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer.

Authors:  P Whitford; E A Mallon; W D George; A M Campbell
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

10.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Authors:  Achim Rody; Uwe Holtrich; Laos Pusztai; Cornelia Liedtke; Regine Gaetje; Eugen Ruckhaeberle; Christine Solbach; Lars Hanker; Andre Ahr; Dirk Metzler; Knut Engels; Thomas Karn; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2009-03-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.